Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm and was the first
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …

The introduction of tyrosine kinase inhibitors (TKIs), a treatment of chronic myelogenous
leukemia (CML), has largely replaced curative strategies based on allogeneic stem cell …

Pediatric cancers differ from adult tumors, especially by their very low mutational rate.
Therefore, their etiology could be explained in part by other oncogenic mechanisms such as …

Patients with chronic myeloid leukemia (CML) in the chronic phase receiving tyrosine kinase
inhibitor (TKI) therapy are expected to have long-term survival outcomes comparable to …

Posttransplant leukemia detection before overt relapse is key to the success of
immunotherapeutic interventions, as they are more efficient when leukemia burden is low …

Results 76 patients (39 men) participated, mean age 67 years, median follow-up 3.6 years.
The response to chemotherapy was heterogeneous and MRD pre-treatment did not predict …

Imatinib will become generic in 2016; assuming that its price will decrease precipitously, we
expect that the economic forces will change our current practice habits. We reviewed the …

Recently, we detected a new fusion transcript LMO3-BORCS5 in a patient with Ewing
sarcoma within a cohort of relapsed pediatric cancers. LMO3-BORCS5 was as highly …

Due to the remarkable success of tyrosine kinase inhibitors (TKI) in chronic myeloid
leukemia (CML), allogeneic stem cell transplantation (alloSCT) is not first-line treatment for …

Introduction The peptide-based cancer vaccine targeting Wilms' tumor 1 (WT1) is a
promising immunotherapeutic strategy for hematological malignancies. It remains unclear …